BullFrog AI Holdings (BFRG) Research & Development (2022 - 2026)
BullFrog AI Holdings' (BFRG) quarterly Research & Development came in at $339456.0 in Q2 2026, down 29.32% on a YoY basis from $480297.0 in Q2 2025, and down 14.54% quarter-over-quarter from $397189.0 in Q4 2025.
Analysis
BullFrog AI Holdings (BFRG) Research & Development (2022 - 2026) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Research & Development for 5 consecutive years, with $339456.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development fell 29.32% year-over-year to $339456.0; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (down 29.41% YoY), and the FY2025 full-year result was $1.8 million, down 19.05% from the prior year.
- Research & Development fell to $339456.0 in Q2 2026 per BFRG's latest filing, from $397189.0 in the prior quarter.
- Across five years, Research & Development topped out at $590856.0 in Q4 2024 and bottomed at $39421.0 in Q3 2022.
- Historically, Research & Development has averaged $376726.1 across 5 years, with a median of $380015.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Research & Development surged 863.99% in 2023, then slumped 38.93% in 2025.
- Over 5 years, Research & Development stood at $160895.0 in 2022, then surged by 154.2% to $408995.0 in 2023, then jumped by 44.47% to $590856.0 in 2024, then sank by 32.78% to $397189.0 in 2025, then dropped by 14.54% to $339456.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $339456.0, $397189.0, and $345992.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 210.03 Mn |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | 339,456.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 339,456.00 |
| Dec 31, 2025 | 397,189.00 |
| Sep 30, 2025 | 345,992.00 |
| Jun 30, 2025 | 480,297.00 |
| Mar 31, 2025 | 576,260.00 |
| Dec 31, 2024 | 590,856.00 |
| Sep 30, 2024 | 566,584.00 |
| Jun 30, 2024 | 513,699.00 |
| Mar 31, 2024 | 552,126.00 |
| Dec 31, 2023 | 408,995.00 |
| Sep 30, 2023 | 380,015.00 |
| Jun 30, 2023 | 273,671.00 |
| Mar 31, 2023 | 369,933.00 |
| Dec 31, 2022 | 160,895.00 |
| Sep 30, 2022 | 39,421.00 |
| Jun 30, 2022 | 92,671.00 |
| Mar 31, 2022 | 316,283.00 |